Why the study?
Does vasoactive intestinal peptide improve inotropic and pulmonary vasodilatory effects in monocrotaline-induced pulmonary hypertensive rabbits following cardiopulmonary bypass compared to isoproterenol and nitroglycerine?
Does vasoactive intestinal peptide improve inotropic and pulmonary vasodilatory effects in monocrotaline-induced pulmonary hypertensive rabbits following cardiopulmonary bypass compared to isoproterenol and nitroglycerine?
Vasoactive intestinal peptide demonstrates dose-responsive positive inotropic and pulmonary vasodilatory effects in a rabbit model of pulmonary hypertension following cardiopulmonary bypass.
Provides preclinical support for VIP post-CPB in pulmonary hypertension; leaves open human translation.
VIP has dose responsive, positive inotropic and pulmonary vasodilatory effects in whole body CPB model acting via calcium channels.
No takes yet. Share an insight, caveat, or question.
Serdar Günaydın (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: